Results 61 to 70 of about 57,995 (263)

Are We Making Smart Pumps Smarter? [PDF]

open access: yes, 2018
Background: Medication errors comprise a significant proportion of medical errors, and are abundant, costly, and associated with causing harm to patients via adverse drug events. The most serious medication errors often involve IV medications.
Schaefer, Brittany
core   +1 more source

Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

open access: yesBMC Cancer, 2020
Background This analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis), nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its treatments randomised ...
Nikki McCaffrey   +11 more
doaj   +1 more source

99mTc-MIBI Lung Scintigraphy in the Assessment of Pulmonary Involvement in Interstitial Lung Disease and Its Comparison With Pulmonary Function Tests and High-Resolution Computed Tomography: A Preliminary Study [PDF]

open access: yes, 2015
The differentiation of active inflammatory processes from an inactive form of the disease is of great value in the management of interstitial lung disease (ILD).
Assadi, M.   +6 more
core   +2 more sources

Unlocking Biomolecule Modification with Light‐Promoted Photocatalyst‐Free Approaches: Current Tools, Challenges, and Perspectives

open access: yesChemistryEurope, EarlyView.
This Perspective focuses on photocatalyst‐free, photoinduced modifications of biomolecules, emphasizing transformations mediated by electron donor–acceptor complexes. Mechanistic aspects, current limitations, and future opportunities are discussed, providing insight into the field of bioconjugation.
Milene Hornink   +3 more
wiley   +1 more source

Beneficial effects of octreotide in alcohol-induced neuropathic pain. Role of H 2S, BDNF, TNF-α and Nrf2

open access: yesActa Cirúrgica Brasileira, 2021
Purpose To explore the role and molecular mechanisms of neuroprotective effects of octreotide in alcohol-induced neuropathic pain. Methods Male Wistar rats were employed and were administered a chronic ethanol diet containing 5% v/v alcohol for 28 days.
Rongqiang Jiang, Hongxia Wei
doaj   +1 more source

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

open access: yesBMC Endocrine Disorders, 2016
BackgroundMany patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR had significantly superior efficacy over ...
M. Bronstein   +12 more
semanticscholar   +1 more source

Pheochromocytoma and Diffuse Large B‐Cell Lymphoma in the Ipsilateral Adrenal Gland: A Case Report

open access: yesIJU Case Reports, EarlyView.
ABSTRACT Introduction Pheochromocytoma is a catecholamine‐producing tumor arising from the adrenal medulla. When it coexists with a tumor of different origin within the same adrenal gland, it is classified as a collision tumor involving a pheochromocytoma.
Ken Maekawa   +9 more
wiley   +1 more source

Randomized controlled study of the effect of octreotide on pancreatic exocrine secretion and pancreatic fistula after pancreatoduodenectomy

open access: yesAsian Journal of Surgery, 2019
Summary: Background: Octreotide is known to decrease the rate of postoperative complication after pancreatic resection by diminishing exocrine function of the pancreas.
Dong Do You   +3 more
doaj   +1 more source

Acromegaly: pathogenesis & treatment [PDF]

open access: yes, 2019
Acromegaly is a multi-system disorder whose etiology is most often traced back to a growth hormone-secreting pituitary adenoma (PA). Growth hormone (GH) secretion promotes insulin-like growth factor 1 (IGF-1) release from peripheral tissues, leading to ...
Tilvawala, Megha
core  

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues [PDF]

open access: yes, 2015
In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues ...
Eriksson, B.   +18 more
core   +3 more sources

Home - About - Disclaimer - Privacy